These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1637888)

  • 1. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
    Mizon P; Goudemand J; Jude B; Marey A
    Ann Hematol; 1992 Jun; 64(6):309-11. PubMed ID: 1637888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H; Ewenstein B
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience.
    Tjønnfjord GE
    Haemophilia; 2004 Sep; 10 Suppl 2():41-5. PubMed ID: 15385045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events.
    Ehrlich HJ; Henzl MJ; Gomperts ED
    Haemophilia; 2002 Mar; 8(2):83-90. PubMed ID: 11952842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of F.IX-inhibitor bypassing activity contained in a commercial prothrombin complex concentrate (Proplex)].
    Sugimoto M; Fujimura Y; Okubo Y; Takahashi Y; Yoshioka A; Fukui H
    Nihon Ketsueki Gakkai Zasshi; 1984 Aug; 47(5):1181-9. PubMed ID: 6516702
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates.
    Chistolini A; Mazzucconi MG; Tirindelli MC; La Verde G; Ferrari A; Mandelli F
    Acta Haematol; 1990; 83(3):163-5. PubMed ID: 2109459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A.
    Gruen DR; Winchester PH; Brill PW; Ramirez E
    Pediatr Radiol; 1997 Mar; 27(3):271-2. PubMed ID: 9126591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
    Barthels M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
    Bardin JM; Sultan Y
    Transfusion; 1990 Jun; 30(5):441-3. PubMed ID: 2360238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor.
    Karayalcin G; Goldberg B; Cherrick I; Kurer C; Bierman F; Lanzkowsky P
    Am J Pediatr Hematol Oncol; 1993 Nov; 15(4):416-9. PubMed ID: 8214364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
    Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
    Barg AA; Levy-Mendelovich S; Avishai E; Dardik R; Misgav M; Kenet G; Livnat T
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27381. PubMed ID: 30230231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.